Published: March 08, 2019
‘Rapid acting’ esketamine was approved by the FDA to treat people who don’t respond to traditional psychiatric drugs
Experts are cautiously optimistic a drug related to ketamine, recently approved by the US Food and Drug Administration, could be a “watershed” moment in the treatment of depression, and one of the first drugs to be a “rapid acting” medicine to treat the chronic disease.
The new drug, called esketamine, will be sold under the brand name Spravato, and was approved to treat people with depression who don’t respond to traditional psychiatric drugs.
Continue reading...from The Guardian https://ift.tt/2EKOva3
via
0 Comments